How it works
Because the cells are intentionally inactivated, they do not need to remain alive or colonize the intestine. Preserved microbial components can remain biologically active and participate in gut–host signaling.
A SOURCE-VERIFIED RESEARCH GUIDE · REVIEWED AUGUST 2026
TRILIVY™ RESET FUELINGS
Three pathways.
One smarter
fueling strategy.
MetaVantage Technology™ brings together a strain-specific postbiotic, chromium picolinate, and choline—three clinically studied ingredients selected to support different, complementary jobs in metabolism.
01GUT
02INSULIN
03LIVER
THREE DISTINCT JOBS.
ONE COORDINATED SYSTEM.
3TARGETED
INGREDIENTS
INGREDIENTS
28INGREDIENT
STUDIES
STUDIES
3METABOLIC
PATHWAYS
PATHWAYS
REAL INGREDIENTS.
REAL CONTEXT.
WHAT IS METAVANTAGE TECHNOLOGY™?
Metabolism isn’t one switch.
It’s a connected system.
MetaVantage Technology™ is Trilivy’s platform of targeted ingredient formulas. In Reset Fuelings, three ingredients add pathway-specific support to a structured nutritional foundation.
A Fueling is not simply a capsule containing three isolated compounds. It provides controlled portions, high-quality protein, fiber, and essential nutrients. MetaVantage Technology™ adds support for gut-derived metabolic signaling, normal insulin function, and normal fat metabolism.
VIEW THE OFFICIAL METAVANTAGE TECHNOLOGY™ OVERVIEW ↗The formula’s strength is pathway complementarity: different ingredients supporting different metabolic jobs.
01
GUT
METAVANTAGE TECHNOLOGY™ INGREDIENT
POSTBIOTIC
Heat-treated Bifidobacterium animalis subsp. lactis CECT 8145
PRIMARY ROLE
Gut-derived metabolic signaling
Gut → central adiposity
A strain-specific, heat-treated bacterial preparation—often called BPL1 in the scientific literature—studied for waist-related and visceral-adiposity measures.
Why it fits
The exact heat-treated strain has been studied in adults with abdominal obesity. That gives it a direct, clinically relevant connection to central-adiposity support inside a structured weight-management program.
WHAT THE EVIDENCE SUPPORTS
- Exact strain and heat-treated form identified
- Human evidence includes waist and visceral-fat measures
- Stable, inanimate preparation
IMPORTANT BOUNDARIES
- Effects from other postbiotics cannot be assigned to CECT 8145
- Preclinical mechanisms are not human outcomes
- Not a stand-alone obesity treatment
CLINICAL RESEARCH
Read the evidence.
8 selected published studies and reviews, prioritized by directness and study design.
01 DIRECT HUMAN RCTPedret et al., 2019
DesignRandomized, double-blind, placebo-controlled; 135 adults with abdominal obesity; 3 months.
What it foundThe heat-killed form improved waist-related measures; visceral fat area, HOMA-IR, and diastolic blood pressure also decreased.
Keep in perspectiveThe exact strain and form were tested, but subgroup findings were stronger in women and industry relationships were disclosed.
View published record02 FOOD-MATRIX RCTCompanys et al., 2022
DesignRandomized, double-blind, placebo-controlled; 120 adults with abdominal obesity; 12 weeks.
What it foundAn enriched food containing heat-inactivated CECT 8145 lowered fasting insulin, HOMA-IR, and post-meal triglyceride rise.
Keep in perspectiveThe food also contained inulin and omega-3s, so the result cannot be attributed to CECT 8145 alone.
View published record03 STRAIN-SPECIFIC HUMAN STUDYAmat-Bou et al., 2020
DesignRandomized crossover trial; 39 children and adolescents with Prader–Willi syndrome; live BPL1 form.
What it foundNo overall change in total fat mass, but abdominal adiposity fell in a prespecified age subgroup and insulin markers improved.
Keep in perspectiveSupportive strain-specific evidence, but the population and live form differ from the Reset ingredient.
View published record04 SYSTEMATIC REVIEWEslami et al., 2024
DesignSystematic review of 49 postbiotic intervention studies, including 9 human studies.
What it foundCECT 8145 was among inactivated strains associated with anthropometric or body-composition improvements in human research.
Keep in perspectiveMost postbiotic evidence was preclinical and preparations were heterogeneous.
View published record05 RCT META-ANALYSISLi et al., 2025
DesignSystematic review and meta-analysis of 25 randomized postbiotic trials.
What it foundPostbiotics modestly reduced insulin, triglycerides, waist circumference, and C-reactive protein overall.
Keep in perspectiveCategory-level evidence; it does not prove a CECT 8145-specific effect.
View published record06 PRECLINICAL · EXACT FORMCaimari et al., 2017
DesignControlled obesity-model study using heat-killed CECT 8145.
What it foundThe intervention increased lean mass and improved several insulin-sensitivity and lipid-related measures.
Keep in perspectiveUseful biological plausibility; animal findings cannot be presented as human outcomes.
View published record07 EARLY MECHANISTIC WORKMartorell et al., 2016
DesignStrain-selection study in Caenorhabditis elegans.
What it foundCECT 8145 reduced lipid and triglyceride accumulation and altered energy-metabolism pathways.
Keep in perspectiveA discovery model, not an estimate of human weight loss.
View published record08 BIOACTIVE COMPONENTBalaguer et al., 2022
DesignMechanistic study of lipoteichoic acid isolated from BPL1.
What it foundReduced fat deposition through insulin/IGF-1-related signaling in C. elegans.
Keep in perspectiveA candidate mechanism that has not been confirmed as the sole pathway in humans.
View published record
02
INSULIN
METAVANTAGE TECHNOLOGY™ INGREDIENT
CHROMIUM PICOLINATE
PRIMARY ROLE
Normal insulin function
Insulin → glucose handling
A widely studied chromium compound included to support the insulin-mediated handling of glucose and other nutrients after a meal.
How it works
Chromium has been proposed to influence insulin signaling at or near the insulin receptor. Human responses vary: benefits appear more likely when baseline glucose control is poorer or insulin resistance is greater, while healthy-adult trials are often neutral.
Why it fits
A structured Fueling controls the nutritional input. Chromium picolinate addresses a hormonal system that helps handle that input. Its role is normal insulin support—not making carbohydrate disappear or acting as a direct fat burner.
WHAT THE EVIDENCE SUPPORTS
- Substantial randomized human literature
- Most relevant to insulin and glucose handling
- Response may depend on baseline metabolic status
IMPORTANT BOUNDARIES
- Not an independent weight-loss ingredient
- High-dose diabetes trials cannot be transferred to a food dose
- Does not replace medical treatment
CLINICAL RESEARCH
Read the evidence.
10 selected published studies and reviews, prioritized by directness and study design.
01 LANDMARK RCTAnderson et al., 1997
DesignRandomized dose-comparison trial; 180 adults with type 2 diabetes; 4 months.
What it foundThe 1,000-microgram group had lower fasting and glucose-challenge values; chromium groups also improved insulin and HbA1c measures.
Keep in perspectivePharmacologic doses and a diabetes population; magnitude cannot be transferred to an unspecified food dose.
View published record02 INSULIN-SENSITIVITY RCTMartin et al., 2006
DesignDouble-blind 6-month trial in adults with type 2 diabetes taking a sulfonylurea.
What it foundChromium improved insulin sensitivity and glycemic control and limited gains in body weight and abdominal fat.
Keep in perspectiveThe randomized phase was small and applies to a specific medicated population.
View published record03 RESPONSE-PREDICTION RCTWang et al., 2007
DesignDouble-blind randomized study; 73 adults with type 2 diabetes; 6 months.
What it foundBaseline insulin sensitivity explained about 40% of the variance in response.
Keep in perspectiveHelps explain why different chromium trials can produce conflicting averages.
View published record04 CLINICAL RCTPaiva et al., 2015
DesignRandomized, single-blind; 71 adults with poorly controlled type 2 diabetes; 4 months.
What it foundFasting and post-meal glucose and HbA1c improved; lipids did not materially improve.
Keep in perspectivePoor baseline control created greater opportunity for improvement.
View published record05 SYSTEMATIC REVIEWSuksomboon et al., 2014
DesignSystematic review of 25 randomized trials in diabetes.
What it foundPooled results found modest HbA1c and fasting-glucose improvements, with more favorable findings in poor baseline control.
Keep in perspectiveForms, doses, co-ingredients, and study quality varied.
View published record06 GLYCEMIC META-ANALYSISAsbaghi et al., 2020
DesignMeta-analysis of 28 randomized trials in type 2 diabetes.
What it foundPooled reductions appeared in fasting glucose, insulin, HbA1c, and HOMA-IR.
Keep in perspectiveVery high heterogeneity means the size and consistency of response varied substantially.
View published record07 RIGOROUS NEUTRAL RCTIqbal et al., 2009
DesignRandomized, double-blind, placebo-controlled; 63 adults with obesity and metabolic syndrome; 16 weeks.
What it foundNo improvement in insulin sensitivity, weight, lipids, inflammation, or most metabolic measures.
Keep in perspectiveStrong evidence that response is not universal and baseline phenotype matters.
View published record08 WEIGHT-LOSS RCTYazaki et al., 2010
DesignRandomized, double-blind, placebo-controlled; 80 otherwise healthy adults with overweight; 24 weeks.
What it foundChromium did not improve BMI or weight loss, and baseline central adiposity did not modify the response.
Keep in perspectiveDirectly argues against positioning chromium as a stand-alone weight-loss agent.
View published record09 CONTROLLED-DIET RCTLukaski et al., 2007
DesignDouble-blind randomized trial; 83 women eating controlled, balanced diets for 12 weeks.
What it foundChromium did not independently affect body weight, fat mass, or lean mass.
Keep in perspectiveTight dietary control reduces the chance that intake differences confounded the result.
View published record10 BODY-COMPOSITION META-ANALYSISVajdi et al., 2024
DesignDose-response meta-analysis of 14 randomized trials in type 2 diabetes.
What it foundNo significant overall effect on weight, BMI, waist circumference, or fat mass.
Keep in perspectiveConfirms that the stronger evidence frame is insulin support, not direct fat loss.
View published record
03
LIVER
METAVANTAGE TECHNOLOGY™ INGREDIENT
CHOLINE
PRIMARY ROLE
Normal fat metabolism
Liver → lipid transport
An essential nutrient the liver needs to build phosphatidylcholine, maintain cell membranes, and package and export triglycerides.
How it works
Choline is biochemistry, not a metaphor. When it is severely inadequate, the liver can struggle to export triglycerides in very-low-density lipoproteins, allowing fat to accumulate inside liver cells. Choline also supplies methyl groups and supports cell-membrane integrity.
Why it fits
During an energy-controlled phase, fat is continuously released, transported, oxidized, and repackaged. Choline provides foundational nutritional support for the liver machinery that manages that lipid traffic.
WHAT THE EVIDENCE SUPPORTS
- Established essential nutrient
- Direct biochemical role in hepatic lipid export
- Controlled human depletion–repletion evidence
IMPORTANT BOUNDARIES
- Adequacy evidence is not a dose-response promise
- Not a stimulant, detox, or direct fat burner
- Disease-treatment trials may use different forms and doses
CLINICAL RESEARCH
Read the evidence.
10 selected published studies and reviews, prioritized by directness and study design.
01 CONTROLLED HUMAN FEEDINGZeisel et al., 1991
DesignHospital-based controlled semisynthetic diets in healthy men.
What it foundCholine depletion lowered stores and raised alanine aminotransferase, an early sign of liver dysfunction.
Keep in perspectivePivotal evidence that choline is required in human nutrition.
View published record02 DEPLETION–REPLETION STUDYFischer et al., 2007
DesignControlled feeding; 57 adults; serial biomarkers and MRI liver-fat assessment.
What it foundMost men and postmenopausal women—and 44% of premenopausal women—developed fatty liver or muscle damage during depletion; repletion resolved it.
Keep in perspectiveDemonstrates deficiency and adequacy, not that more choline always creates more fat loss.
View published record03 METABOLOMICS STUDYSha et al., 2010
Design53 participants in a controlled depletion–repletion protocol with liver-fat spectroscopy.
What it foundBaseline metabolic patterns predicted who developed liver dysfunction during deprivation.
Keep in perspectiveRelated to the same broader feeding program as Fischer, not a fully independent replication.
View published record04 MICROBIOME + LIVER STUDYSpencer et al., 2011
DesignTwo-month inpatient study; 15 women; controlled diets with manipulated choline.
What it foundSpecific gut-microbial changes plus a host genetic variant predicted liver-fat accumulation during depletion.
Keep in perspectiveA small deficiency-physiology study, not routine weight-loss supplementation.
View published record05 CLINICAL REVERSAL STUDYBuchman et al., 1995
DesignFour long-term parenteral-nutrition patients with low choline and hepatic steatosis.
What it foundIntravenous choline normalized plasma levels and resolved CT-estimated steatosis; one recurrence followed return to choline-free nutrition.
Keep in perspectiveCompelling causal sequence in a very small, medically complex population.
View published record06 PLACEBO-CONTROLLED PILOTBuchman et al., 2001
DesignPlacebo-controlled pilot; 15 adults receiving long-term parenteral nutrition; 2 grams per day of intravenous choline for 24 weeks.
What it foundLiver CT density and several liver-enzyme measures improved versus control; steatosis recurred 10 weeks after supplementation stopped.
Keep in perspectiveA specialized deficiency setting and intravenous dose; it is not comparable to routine dietary intake or a Fueling.
View published record07 LARGE POPULATION STUDYYu et al., 2014
DesignObservational analysis of 56,195 Chinese adults.
What it foundHigher dietary choline was associated with lower fatty-liver odds before full adjustment; the adjusted signal remained clearest in normal-weight women.
Keep in perspectiveLarge real-world sample, but observational and not uniform across groups.
View published record08 BIOPSY-CHARACTERIZED COHORTGuerrerio et al., 2012
Design664 adults and children in a multicenter NASH research network.
What it foundVery low choline intake was associated with more severe fibrosis in postmenopausal women after adjustment.
Keep in perspectiveCross-sectional; it cannot prove that increasing choline reverses fibrosis.
View published record09 U.S. POPULATION EVIDENCEChai et al., 2023
DesignCross-sectional analysis of NHANES 2017–2018.
What it foundCholine-intake status was associated with the likelihood of nonalcoholic fatty liver disease after multivariable adjustment.
Keep in perspectiveAssociation, not causation; dietary recall can introduce measurement error.
View published record10 MODERN CLINICAL RCTSedhom et al., 2025
DesignRandomized, single-blind; 79 patients with nonalcoholic fatty liver disease; 12 weeks.
What it foundHigh-dose phosphatidylcholine improved steatosis, liver enzymes, triglycerides, oxidative stress, and inflammation.
Keep in perspectiveModest size; disease setting, form, and dose may differ from choline in a Reset Fueling.
View published recordHOW THEY WORK TOGETHER
Different jobs.
One coordinated sequence.
The gut provides the first signal.
The heat-treated CECT 8145 postbiotic meets the gastrointestinal environment, where inanimate microbial components can participate in gut–host signaling.
Insulin directs circulating fuel.
As nutrients enter the bloodstream, insulin helps move glucose into cells. Chromium picolinate is included to support that normal function.
The liver manages lipid traffic.
Choline helps supply phosphatidylcholine, which the liver uses to package and export triglycerides as part of normal fat metabolism.
The Fueling supplies structure.
Protein, fiber, portion control, and micronutrients create the predictable foundation in which targeted ingredients operate.
STRUCTURED NUTRITION→GUT SIGNALING→INSULIN-GUIDED HANDLING→FAT TRANSPORT
THE PROGRAM STILL MATTERS
Ingredients support physiology.
The program creates the conditions.
A study of 198 adults found that structured Medifast/OPTAVIA-style programs using pre-portioned meal replacements and behavioral support produced greater reductions in weight, fat mass, abdominal fat, and waist and hip measures than a self-directed diet.
VIEW STUDY ↗A synthesis involving 7,884 adults found that meal-replacement programs improved one-year weight loss versus comparator diets; the largest pooled difference was seen when meal replacements were combined with enhanced support.
VIEW STUDY ↗OUR RESEARCH STANDARD
Credibility needs context.
Evidence was prioritized by directness: exact ingredient and form first, then related human research, systematic reviews, and preclinical work used only for biological plausibility.
- 01Exact ingredient + exact form
Randomized human trials receive the greatest weight.
- 02Related human evidence
Different matrices, doses, forms, or populations are clearly identified.
- 03Systematic synthesis
Reviews and meta-analyses show the wider pattern, including neutral findings.
- 04Mechanistic context
Preclinical research explains plausibility, never promised human outcomes.
WHAT THE RESEARCH SUPPORTS
- Three clinically studied ingredients with complementary metabolic roles.
- Strain-specific human evidence for waist-related and visceral-adiposity measures.
- Normal insulin-function support from chromium picolinate.
- An established role for choline in normal lipid transport and metabolism.
- Structured meal-replacement programs paired with support can improve weight-management outcomes.
WHAT IT DOES NOT MEAN
- No ingredient guarantees a specific amount of weight, fat, or waist loss.
- Chromium picolinate is not an independent fat burner.
- Choline supports normal transport; it is not a detox treatment.
- High-dose supplement results cannot be assumed for a food product unless form and dose match.
- Nutrition products do not replace diagnosis, medication, or individualized medical care.
FREQUENTLY ASKED
Clear answers.
No shortcuts.
What are the three ingredients?+
Heat-treated Bifidobacterium animalis subsp. lactis CECT 8145, chromium picolinate, and choline.
Is CECT 8145 a probiotic or a postbiotic?+
The Reset ingredient is heat-treated, so it is a postbiotic: an inanimate microbial preparation whose components can still interact with the host. Live-form studies are supportive but are not identical evidence.
Does MetaVantage Technology™ burn fat?+
“Fat burner” is not the accurate frame. The ingredients support metabolic processes; actual fat loss depends on the full plan, energy balance, adherence, activity, biology, and time.
Why include chromium if some studies are neutral?+
Because the evidence is population-dependent. Benefits appear more likely with impaired insulin sensitivity or poorer glucose control. That supports a measured normal-insulin-function claim—not a universal result.
Why does choline matter during weight management?+
Choline is required to make phosphatidylcholine, which helps the liver package and export triglycerides. Its role is nutritional and physiological, not stimulant-like.
SAFETY + APPROPRIATE USE
This page is educational and is not medical advice. People using insulin, metformin, or other glucose-lowering medication should discuss chromium-containing products with their clinician because of possible additive effects. Chromium picolinate can also reduce levothyroxine absorption when taken at the same time.
People with kidney or liver disease, those who are pregnant or breastfeeding, and anyone under active medical care should review the current product label and program with a qualified healthcare professional. Published supplement-trial doses are not necessarily the amounts in Trilivy Reset Fuelings.